Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine

Infection and Immunity

Volumn 70, Issue 2, 2002, Pages 702-707

  Katial, Rohit K ^a   Brandt, Brenda L ^a   Moran, Ellen E ^a   Marks, Stephen ^a   Agnello, Victor ^a   Zollinger, Wendell D ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MENINGOCOCCAL NATIVE OUTER MEMBRANE VESICLE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; CELL INFILTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; LICENSING; MALE; MEMBRANE VESICLE; MENINGITIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; VACCINATION;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CONSUMER PRODUCT SAFETY; DRUG TOLERANCE; FEMALE; HUMANS; IMMUNOGLOBULIN ISOTYPES; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; VACCINATION; VACCINES, SYNTHETIC;

EID: 0036156090     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.2.702-707.2002     Document Type: Article

References (19)

1. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
2. Efficacy, safety and immunogenicity of a meningococcal group B (15: P1.3) outer membrane protein vaccine in Iquique, Chile
3. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
4. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil
5. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers
6. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and non-human primates
7. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans
8. Cytologic diagnosis in respiratory allergy and infection
9. Development of antibodies to meningococcal proteins and lipopolysaccharide antigens in healthy carriers
10. Measurement of antibodies to meningococcal group B polysaccharide: Low avidity binding and equilibrium binding constants
11. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity
12. The changing epidemiology of meningococcal disease in the United States, 1992-1996
13. Immunogenicity of intranasally administered meningococcal native outer membrane vesicle in mice
14. Confirmation of suspicious cases of meningococcal meningitis by PCR and enzyme-linked immunosorbent assay
15. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba
16. Isolation and characterization of a native cell wall complex from Neisseria meningitidis
17. Importance of the complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide
18. Enhancement of immunological activity by noncovalent complexing of meningococcal group B polysaccharide and outer membrane proteins
19. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man